CTI-CLINICAL
14.7.2021 16:32:10 CEST | Business Wire | Press release
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Dynakin , a contract research organization with a GLP biolab and model-based drug development services that has nearly two decades of experience and strong local expertise across Europe.
CTI is working to expand laboratory services to support rare disease and cell & gene therapy research across all regions of the world , with a flagship lab being built in Cincinnati, OH (covering the Americas), and now Dynakin’s laboratory services will support Europe and the MEA region. Dynakin’s Drug Modeling (pharmacometrics) services is complementary to CTI’s Regulatory and Scientific Affairs group, and provides support and/or confirmation of dosing & regulatory decisions at all development stages, as well as optimal design of clinical trials. Dynakin’s CRO services will be merged into CTI’s European clinical team. Dynakin co-founders Dr. Monica Rodriguez and Dr. Nerea Leal will be joining CTI in new roles that will be integral to the company’s growth.
“We are excited to have Dynakin join CTI to create a stronger and more robust global full-service clinical research organization,” according to Timothy J. Schroeder, CTI’s Chairman & CEO. “Dynakin and CTI share common philosophies and cultures, with a focus on teamwork, employee retention and career development. We are passionate about continued growth and expansion for the continued success of the company, so this acquisition is a great fit for the next phase of growth at CTI.”
CTI, now in its third decade, is one of the 20 largest CROs in the world, with associates in more than 60 countries across six continents. The company was recently named the #1 CRO in the world for operational excellence at the 2021 CRO Leadership Awards , outperforming nearly 30 other recognized CROs from around the world.
The terms of the acquisition were not disclosed.
About CTI
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005127/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
Balderton Welcomes Serial Entrepreneur Phil Chambers as Partner23.4.2026 07:00:00 CEST | Press release
Balderton today announces the appointment of Phil Chambers as Partner, where he will focus on early-stage investments. Phil joins the firm after a 20+ year career as a founder, operator and angel investor in the European technology ecosystem, including roles in London, Hamburg and Copenhagen. Most recently, he served as CEO of Orbex, the Scottish space launch company, which was selected as one of the 5 winners of ESA’s European Launcher Challenge. Prior to Orbex, Phil co-founded and was the CEO of Peakon, a Balderton portfolio company focused on employee engagement, which he led through rapid international expansion from its Danish home, into the UK, Germany, the US and APAC before its $700 million acquisition by Workday in 2021. He was then GM at Workday for two and a half years, where he grew Peakon’s footprint around the world to hundreds of millions in ARR. After falling in love with computers and technology as a child, Phil studied computer science at the University of Manchester
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting23.4.2026 01:52:00 CEST | Press release
The Show’s growing community of creators, enterprise media teams and leaders in sports media is driving the next era of storytelling The 2026 NAB Showwrapped today, welcoming more than 58,000 registered attendees and reaffirming its place at the center of the global media and entertainment evolution. Driven by an expanding community of creators, enterprise media teams and leaders in sports media, the Show has brought in new audiences and sparked new collaborations. The 2026 NAB Show didn’t just reflect where the industry is; it pushed it forward, strengthening its status as the must-attend marketplace for the future of storytelling and content innovation. “The 2026 NAB Show captured the energy and transformation driving today’s media and entertainment landscape, unveiling powerful new tools and technologies that put storytelling in everyone’s hands,” said Karen Chupka, executive vice president of NAB Show. “This year, we brought together a truly global community to spark innovation, el
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom